In this study, we have compared four 68Ga-labeled peptides (three Arg-Gly-Asp (RGD) peptides and substance-P) with two 18F-tracers clinically approved for tumor imaging. We have studied in vitro and in vivo characteristics of selected radiolabeled tracers in a glioblastoma multiforme tumor model. The in vitro part of the study was mainly focused on the evaluation of radiotracers stability under various conditions. We have also determined in vivo stability of studied 68Ga-radiotracers by analysis of murine urine collected at various time points after injection. The in vivo behavior of tested 68Ga-peptides was evaluated through ex vivo biodistribution studies and PET/CT imaging. The obtained data were compared with clinically used 18F-tracers. 68Ga-RGD peptides showed better imaging properties compared to 18F-tracers, i.e., higher tumor/background ratios and no accumulation in non-target organs except for excretory organs.

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc 77900 Olomouc Czech Republic

See more in PubMed

Ladomersky E., Scholtens D.M., Kocherginsky M., Hibler E.A., Bartom E.T., Otto-Meyer S., Zhai L., Lauing K.L., Choi J., Sosman J.A., et al. The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. Front. Pharmacol. 2019;10:200. doi: 10.3389/fphar.2019.00200. PubMed DOI PMC

Ahmed R., Oborski M.J., Hwang M., Lieberman F.S., Mountz J.M. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag. Res. 2014;6:149–170. PubMed PMC

Frosina G. Positron emission tomography of high-grade gliomas. J. Neuro Oncol. 2016;127:415–425. doi: 10.1007/s11060-016-2077-1. PubMed DOI

Frosina G. Non-routine tracers for PET imaging of high-grade glioma. Anticancer Res. 2016;36:3253–3260. PubMed

Chen W. Clinical Applications of PET in Brain Tumors. J. Nucl. Med. 2007;48:1468–1481. doi: 10.2967/jnumed.106.037689. PubMed DOI

Li D., Zhao X., Zhang L., Li F., Ji N., Gao Z., Wang J., Kang P., Liu Z., Shi J., et al. 68Ga-PRGD2 PET/CT in the Evaluation of Glioma: A Prospective Study. Mol. Pharm. 2014;11:3923–3929. doi: 10.1021/mp5003224. PubMed DOI PMC

Schnell O., Krebs B., Wagner E., Romagna A., Beer A.J., Grau S.J., Thon N., Goetz C., Kretzschmar H.A., Tonn J.C., et al. Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 2008;18:378–386. doi: 10.1111/j.1750-3639.2008.00137.x. PubMed DOI PMC

Holmes K.M., Annala M., Chua C.Y.X., Dunlap S.M., Liu Y., Hugen N., Moore L.M., Cogdell D., Hu L., Nykter M., et al. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc. Natl. Acad. Sci. USA. 2012;109:3475–3480. doi: 10.1073/pnas.1120375109. PubMed DOI PMC

Nieberler M., Reuning U., Reichart F., Notni J., Wester H.-J., Schwaiger M., Weinmüller M., Räder A., Steiger K., Kessler H. Exploring the Role of RGD-Recognizing Integrins in Cancer. Cancers. 2017;9:116. doi: 10.3390/cancers9090116. PubMed DOI PMC

Haubner R., Weber W.A., Beer A.J., Vabuliene E., Reim D., Sarbia M., Becker K.F., Goebel M., Hein R., Wester H.J., et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2:e70. doi: 10.1371/journal.pmed.0020070. PubMed DOI PMC

Li Z.B., Chen K., Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur. J. Nucl. Med. Mol. Imaging. 2008;35:1100–1108. doi: 10.1007/s00259-007-0692-y. PubMed DOI

Knetsch P.A., Petrik M., Griessinger C.M., Rangger C., Fani M., Kesenheimer C., Von Guggenberg E., Pichler B.J., Virgolini I., Decristoforo C., et al. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging. 2011;38:1303–1312. doi: 10.1007/s00259-011-1778-0. PubMed DOI

Haubner R., Kuhnast B., Mang C., Weber W.A., Kessler H., Wester H.-J., Schwaiger M. [18F]Galacto-RGD: Synthesis, Radiolabeling, Metabolic Stability, and Radiation Dose Estimates. Bioconjugate Chem. 2004;15:61–69. doi: 10.1021/bc034170n. PubMed DOI

Rangger C., Helbok A., Sosabowski J., Kremser C., Koehler G., Prassl R., Andreae F., Virgolini I.J., Von Guggenberg E., Decristoforo C., et al. Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles. Int. J. Nanomed. 2013;8:4659–4671. doi: 10.2147/IJN.S51927. PubMed DOI PMC

Brahm C.G., Hollander M.W.D., Enting R.H., De Groot J.C., Solouki A.M., Dunnen W.F.A.D., Heesters M.A.A.M., Wagemakers M., Verheul H.M.W., De Vries E.G.E., et al. Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. Eur. J. Nucl. Med. Mol. Imaging. 2018;45:2404–2412. doi: 10.1007/s00259-018-4090-4. PubMed DOI PMC

Muñoz M., Coveñas R., Esteban F., Redondo M. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. J. Biosci. 2015;40:441–463. doi: 10.1007/s12038-015-9530-8. PubMed DOI

Isal S., Pierson J., Imbert L., Clement A., Collet C., Pinel S., Veran N., Reinhard A., Poussier S., Gauchotte G., et al. PET imaging of 68Ga-NODAGA-RGD, as compared with 18F-fluorodeoxyglucose, in experimental rodent models of engrafted glioblastoma. EJNMMI Res. 2018;8:51. doi: 10.1186/s13550-018-0405-5. PubMed DOI PMC

Delgado-López P.D., Riñones-Mena E., Corrales-García E.M. Treatment-related changes in glioblastoma: A review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis. Clin. Transl. Oncol. 2018;20:939–953. doi: 10.1007/s12094-017-1816-x. PubMed DOI

Lohmann P., Stavrinou P., Lipke K., Bauer E., Ceccon G., Werner J., Neumaier B., Fink G., Shah N., Langen K., et al. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. 57. Jahrestag. der Dtsch. Ges. für Nukl. 2019;58:V54. PubMed

Van Der Gucht A., Pomoni A., Jreige M., Allemann P., Prior J.O. 68Ga-NODAGA-RGDyK PET/CT Imaging in Esophageal Cancer: First-in-Human Imaging. Clin. Nucl. Med. 2016;41:e491–e492. doi: 10.1097/RLU.0000000000001365. PubMed DOI

Zhai C., Franssen G.M., Petrik M., Laverman P., Summer D., Rangger C., Haubner R., Haas H., Decristoforo C. Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [68Ga]NODAGA-RGD—In Vivo Imaging Studies in Human Xenograft Tumors. Mol. Imaging Boil. 2016;18:758–767. doi: 10.1007/s11307-016-0931-3. PubMed DOI PMC

Shi X., Shen L. Integrin αvβ3 receptor targeting PET/MRI dual-modal imaging probe based on the 64Cu labeled manganese ferrite nanoparticles. J. Inorg. Biochem. 2018;186:257–263. doi: 10.1016/j.jinorgbio.2018.06.004. PubMed DOI

Provost C., Rozenblum-Beddok L., Nataf V., Merabtene F., Prignon A., Talbot J.N. [68Ga]RGD Versus [18F]FDG PET Imaging in Monitoring Treatment Response of a Mouse Model of Human Glioblastoma Tumor with Bevacizumab and/or Temozolomide. Mol. Imaging Biol. 2019;21:297–305. doi: 10.1007/s11307-018-1224-9. PubMed DOI

Eo J.S., Jeong J.M. Angiogenesis Imaging Using 68Ga-RGD PET/CT: Therapeutic Implications. Semin. Nucl. Med. 2016;46:419–427. doi: 10.1053/j.semnuclmed.2016.04.001. PubMed DOI

Chen X., Liu S., Hou Y., Tohme M., Park R., Bading J.R. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 2004;6:350–359. doi: 10.1016/j.mibio.2004.06.004. PubMed DOI

Burmeister A.R., Johnson M.B., Chauhan V.S., Moerdyk-Schauwecker M.J., Young A.D., Cooley I.D., Martinez A.N., Ramesh G., Philipp M.T., Marriott I. Human microglia and astrocytes constitutively express the neurokinin-1 receptor and functionally respond to substance P. J. Neuroinflammation. 2017;14:245. doi: 10.1186/s12974-017-1012-5. PubMed DOI PMC

Liu S., Liu Z., Chen K., Yan Y., Watzlowik P., Wester H.J., Chin F.T., Chen X. 18F-abeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol. Imaging Biol. 2010;12:530–538. doi: 10.1007/s11307-009-0284-2. PubMed DOI PMC

Mozaffari S., Erfani M., Beiki D., Daha F.J., Kobarfard F., Balalaie S., Fallahi B. Synthesis and preliminary evaluation of a new (99m)tc labeled substance p analogue as a potential tumor imaging agent. Iran. J. Pharm. Res. 2015;14:97–110. PubMed PMC

Rinne P., Silvola J.M.U., Hellberg S., Ståhle M., Liljenbäck H., Salomäki H., Koskinen E., Nuutinen S., Saukko P., Knuuti J., et al. Pharmacological Activation of the Melanocortin System Limits Plaque Inflammation and Ameliorates Vascular Dysfunction in Atherosclerotic Mice. Arter. Thromb. Vasc. Boil. 2014;34:1346–1354. doi: 10.1161/ATVBAHA.113.302963. PubMed DOI

Chan S.R., Salem K., Jeffery J., Powers G.L., Yan Y., Shoghi K.I., Mahajan A.M., Fowler A.M. Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations with 18F-FLT. J. Nucl. Med. 2018;59:833–838. doi: 10.2967/jnumed.117.199406. PubMed DOI PMC

Monaco A., Zoete V., Alghisi G.C., Rüegg C., Michelin O., Prior J., Scapozza L., Seimbille Y. Synthesis and in vitro evaluation of a novel radioligand for αvβ3 integrin receptor imaging: [18F]FPPA-c(RGDfK) Bioorg. Med. Chem. Lett. 2013;23:6068–6072. doi: 10.1016/j.bmcl.2013.09.031. PubMed DOI

Xu H.-L., Li M., Zhang R.-J., Jiang H.-J., Zhang M.-Y., Li X., Wang Y.-Q., Pan W.-B. Prediction of tumor biological characteristics in different colorectal cancer liver metastasis animal models using 18 F-FDG and 18 F-FLT. Hepatobiliary Pancreat. Dis. Int. 2018;17:140–148. doi: 10.1016/j.hbpd.2018.03.006. PubMed DOI

Liu J., Yuan S., Wang L., Sun X., Hu X., Meng X., Yu J. Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer: A Systematic Review and Meta-Analysis. BioMed Res. Int. 2019;2019:1–15. doi: 10.1155/2019/8534761. PubMed DOI PMC

Müller S.A., Holzapfel K., Seidl C., Treiber U., Krause B.J., Senekowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur. J. Nucl. Med. Mol. Imaging. 2009;36:1434–1442. doi: 10.1007/s00259-009-1117-x. PubMed DOI

Yardeni T., Eckhaus M., Morris H.D. Retro-orbital injections in mice. Lab Anim. 2011;40:155–160. doi: 10.1038/laban0511-155. PubMed DOI PMC

68Ga]Ga-DFO-c(RGDyK): Synthesis and Evaluation of Its Potential for Tumor Imaging in Mice